Quassia (Quassia amara)

Quassia amara is an Amazonian tree whose bark contains quassinoids, bitter compounds that demonstrate antimalarial and anti-inflammatory properties. These bioactive compounds work by inhibiting protein synthesis in Plasmodium parasites and reducing inflammatory cell adhesion.

Origin & History

Quassia derives from the wood of the Quassia amara tree, a species native to South America in the Simaroubaceae family. It is typically extracted using water or ethanol-water mixtures from the dried wood, yielding a powder, chips, shavings, or liquid extract rich in bitter principles called quassinoids.

Historical & Cultural Context

In South American traditional medicine systems, Quassia amara wood has been used for digestive issues, malaria, and hepatic disorders. It has also served as a natural insecticide and repellent against pests like aphids and beetles, with efficacy first reported in 1986 for crop protection.

Health Benefits

• Anti-malarial activity demonstrated through in vitro studies showing quassinoids' antiplasmodial effects against Plasmodium falciparum (preliminary evidence)
• Anti-inflammatory properties via inhibition of leukocyte-endothelial adhesion in laboratory studies (preliminary evidence)
• Digestive support and anti-ulcer activity shown in rat studies with 100 mg/kg reducing gastric juice and acid (preliminary evidence)
• Antitumor effects demonstrated with 81% inhibition of P388 leukemia cells at 200 mg/kg in mice (preliminary evidence)
• Antiviral activity observed in vitro with simikalikalactone D at 0.2-20 µg/ml against poliovirus and HSV-1 (preliminary evidence)

How It Works

Quassinoids, particularly quassin and neoquassin, exert antimalarial effects by inhibiting protein synthesis in Plasmodium falciparum parasites through disruption of ribosomal function. The anti-inflammatory action occurs via inhibition of leukocyte-endothelial adhesion molecules, reducing inflammatory cell migration. These compounds also stimulate digestive secretions by activating bitter taste receptors in the gastrointestinal tract.

Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on Quassia amara. Evidence is limited to preclinical in vitro and animal studies investigating various biological activities including antimalarial, anti-inflammatory, and antitumor effects.

Clinical Summary

In vitro studies have demonstrated quassinoids' antiplasmodial activity against Plasmodium falciparum, showing IC50 values ranging from 0.1-2.4 μM for various quassinoid compounds. Laboratory studies on inflammatory models showed significant reduction in leukocyte adhesion to endothelial cells at concentrations of 10-50 μg/mL. However, human clinical trials are limited, with most evidence coming from traditional use and preliminary laboratory research. Current evidence is considered preliminary and requires further clinical validation.

Nutritional Profile

Quassia (Quassia amara) is a non-nutritive medicinal bitter wood/bark with negligible macronutrient content in therapeutic doses. Primary bioactive compounds are quassinoids (bitter principles), comprising approximately 0.1–0.2% of dry wood weight, dominated by quassin (the most abundant, ~0.08–0.12% dry weight) and 2-methylquassin (~0.03–0.06% dry weight), along with neoquassin, 18-hydroxyquassin, and simalikalactone D. Alkaloids include β-carboline derivatives (1-methylcarboline, 3-methylcarboline, and canthin-6-one) at trace concentrations (~0.01–0.05% dry weight). Flavonoids including quassimarin and scopoletin (a coumarin) are present in minor quantities. The bark and wood contain tannins at approximately 2–5% dry weight contributing to astringency. Polysaccharides (gums and mucilages) are present in small amounts. Mineral content of the crude plant material includes potassium, calcium, and magnesium at low but detectable levels; no significant vitamin content is documented. Quassinoids exhibit high biological potency at extremely low concentrations (IC50 values for quassin in antiplasmodial activity ~1.5–4.0 µM), meaning therapeutic bioactive doses are very small (typical herbal preparations use 0.5–2 g dried wood). Oral bioavailability of quassinoids is considered moderate; quassin undergoes hepatic metabolism and is excreted renally. Bitter compounds stimulate bitter taste receptors (TAS2Rs), mediating digestive secretion effects via cephalic-phase reflex mechanisms even at sub-milligram concentrations.

Preparation & Dosage

No clinically studied human dosages are available. Animal studies used 100-200 mg/kg intraperitoneally in rats for anti-ulcer and antitumor effects, and 50-250 µg/ml in vitro for various activities. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Wormwood, Gentian root, Milk thistle, Artichoke leaf, Dandelion

Safety & Interactions

Quassia is generally considered safe when used short-term as a digestive bitter, but prolonged use may cause gastrointestinal irritation due to its intense bitter compounds. It may interact with diabetes medications by affecting blood sugar levels and could potentially enhance the effects of antimalarial drugs. Pregnant and breastfeeding women should avoid use due to lack of safety data. High doses may cause nausea, vomiting, and abdominal cramping.